HOUSE_OVERSIGHT_024025.jpg

OTHER INVESTMENT PROFESSIONALS

Kathy LaPorte, (52), Venture Partner, is an angel investor in the Digital Health space focusing on evaluating and mentoring start-ups developing digital technology solutions for healthcare consumers, providers, payers and the pharmaceutical/medical device industries. Kathy is affiliated with Health Tech Capital and is a Venture Partner with New Leaf, collaborating on sourcing of opportunities with an emphasis on the Information Convergence sector. Kathy was one of the founders of New Leaf upon its spin out from the Sprout Group in 2005. Kathy joined the Sprout Group in 1993 and became a General Partner in 1994. Between 1987 and 1993, she was a Principal at Asset Management Company, a venture capital firm focused on early stage investments. Kathy received an M.B.A. from Stanford University Graduate School of Business (Arjay Miller Scholar), and a B.S., summa cum laude, Phi Beta Kappa from Yale University.

Mark Charest, Ph.D., (36), Portfolio Manager, joined New Leaf in 2012. Previously, Mark was an Associate and Kauffman Fellow at Panorama Capital (2010-2012) focused on life sciences investments. Mark previously worked as a Consultant at ZS Associates (2009) and as an Associate at Great Point Partners (2007-2009), a healthcare-focused public and private equity investment firm. Prior to that, Mark held an operating role as a Medicinal Chemistry Lab Manager at Novartis Institutes for BioMedical Research (2004-2007). Mark received his Ph.D. in Chemistry and Chemical Biology from Harvard University as a National Science Foundation Graduate Research Fellow.

Mike Dybbs, Ph.D., (39), Principal, joined New Leaf in 2009 and was promoted to Principal in 2012. Mike is currently on the boards of directors of Advanced Cellular Diagnostics and Versartis. Prior to joining New Leaf, Mike was a Principal at the Boston Consulting Group (BCG) where he was a core member of their Health Care practice. Mike graduated magna cum laude from Harvard University with an AB in biochemical sciences and received his Ph.D. in molecular biology and genetics from UC Berkeley, where he was awarded a Howard Hughes Medical Institute fellowship. His research had been published in peer-reviewed journals, including Neuron, Science and Nature.

Eric Kim, (28), Associate, joined New Leaf in December 2013. From 2011 through 2013, Eric was a Private Equity Associate at Francisco Partners, where he focused on diligence and company oversight efforts on the firm’s healthcare information technology portfolio. Prior to joining Francisco Partners, Eric worked for three years at McKinsey & Company as a Senior Business Analyst in their Corporate Finance Practice. Eric received his dual B.A. in Mathematical Methods in the Social Sciences and Economics from Northwestern University.

Isaac Manke, Ph.D., (37), Portfolio Manager, joined New Leaf in 2009 as an Associate and was promoted to Public Investment Director in 2012. Prior to joining New Leaf, Isaac was an Associate in the Global Biotechnology Equity Research group at Sanford C. Bernstein. Previously, Isaac worked as an Associate in the Biotechnology Equity Research group at Deutsche Bank and was a Senior Analyst at Health Advances, a biopharmaceutical and medical device strategy consulting firm. Isaac received a B.A. in Biology and a B.A. in Chemistry at Minnesota State University (Moorhead), and a Ph.D. in Biophysical Chemistry and Molecular Structure at the Massachusetts Institute of Technology (MIT). Isaac’s discoveries led to several publications in top journals, including Science and Cell, and were selected by Science as one of

14
CONTROL NUMBER 257 - CONFIDENTIAL
HOUSE_OVERSIGHT_024025